American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“The American Society of Clinical Oncology’s (ASCO) new living guideline update, Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, is now available.
Updated recommendations include that clinicians can now consider osimertinib combined with platinum-based chemotherapy or the combination of amivantamab and lazertinib as potential treatment options.
Read more.”
